AstraZeneca RSV Preventive Gets Nearly Unanimous AdComm Recommendation
The FDA’s Antimicrobial Drugs Advisory Committee, meeting Thursday, was overwhelmingly positive in its assessment of benefits and risks of AstraZeneca’s respiratory syncytial virus (RSV) preventive treatment, nirsevimab, for children.
Source: Drug Industry Daily